Qiagen N v (QGEN) - News Archive

QIAGEN Expands Digital PCR Offerings and Strengthens Forensic Capabilities Amid Solid Financial Performance In a significant stride towards enhancing life sciences and forensic investigations, QIAGEN NV, a global leader...

Revolutionizing Disease Detection: QIAGEN and Bio-Manguinhos/Fiocruz Enhance Malaria and Dengue Screening in BrazilIn a significant leap for public health in Brazil, QIAGEN and Bio-Manguinhos/Fiocruz have embarked on a...

In a world where both social responsibility and corporate performance are under constant scrutiny, recent developments highlight the intersection of inclusivity and industry challenges. The Abbey Food & Bar, one of West...

In a recent press release, Qiagen N.V. revealed its year-to-date performance, showcasing its promising growth trajectory. The company continues to make strides in the biotechnology industry, positioning itself as a lead...

QIAGEN N.V. Successfully Places Innovative Net Share Settled Convertible Bonds: A Strategic Move Amidst Global Market DynamicsIn a strategic development reflecting both confidence and adaptability in fluctuating global...

QIAGEN N.V. Bolsters Financial Strategy with Non-U.S. Offering of Net Share Settled Convertible BondsIn a strategic financial maneuver, QIAGEN N.V. a prominent player in the biotechnology sector, has announced the launc...

A Hawaiian Dream Come True: Celebrating Anna’s WishIn the serene corridors of Wawasee Middle School, an air of excitement prevailed as 12-year-old Anna experienced a moment she would cherish forever. A Hawaiian-themed p...

QIAGEN Surpasses Expectations in Q2 2024, Poised for Growth Amidst New Guidelines for Tuberculosis Screening Venlo, The Netherlands QIAGEN N.V. (NYSE: QGEN), a prominent player in molecular diagnostics and genomic resea...

QIAGEN and University of Montana Collaborate to Enhance Identification of Human Remains for Indigenous People and African AmericansIn a groundbreaking partnership with the University of Montana, global biotechnology com...

QIAGEN N.V., a leading provider of sample and assay technologies, announced its plans to release the results for the second quarter of 2024. Additionally, the company highlighted the recent improvements in their softwar...

QIAGEN Revolutionizes Tuberculosis Testing in Children with QuantiFERON-TB Gold Plus, Welcomed by New U.S. GuidelinesQIAGEN, a leading provider of innovative molecular diagnostics solutions, has received a significant b...

In an era driven by innovation and sustainable practices, the biotechnology and sustainable resources sectors have witnessed significant breakthroughs. This article explores two pivotal advancements: Kraig Biocraft Labo...

QIAGEN, a global leader in molecular diagnostics and life sciences, continues to revolutionize the field with their latest software and assay releases. In this article, we will highlight their advancements in high-throu...

QIAGEN Achieves ESG Milestones and Advances Product Portfolio Amid Strategic ShiftsIn a robust demonstration of its commitment to environmental, social, and governance (ESG) principles, QIAGEN has published its 2023 sus...

In a groundbreaking move set to influence the landscape of microbial research and infectious disease surveillance, QIAGEN has recently launched an impressive array of new digital PCR assays. These advancements include t...

QIAGEN s Strategic Moves in the Post-Pandemic Market: Discontinuing NeuMoDx Testing System and Expanding Gastrointestinal and HRD TestsIn response to challenging post-pandemic market trends, QIAGEN, a leading provider o...

QIAGEN Empowers Researchers with Enhanced Digital PCR Assay Design Tools and Collaborative Panels to Accelerate Drug Discovery and Customization NeedsIn a move to further bolster their position as a trusted partner for...

In a significant stride towards revolutionizing clinical diagnostics and advancing precision medicine, QIAGEN has announced three major developments, each transforming its respective domain of application. These advance...

In a strategic partnership, QIAGEN and Myriad Genetics have jointly developed a distributable Homologous Recombination Deficiency (HRD) test for both global research and companion diagnostics applications. Leveraging QI...

QIAGEN Advances Precision Medicine with Innovative Library Preparation Kit and Respiratory Testing PanelIn a significant breakthrough for the field of precision medicine, QIAGEN recently launched its QIAseq Multimodal D...